Navigation Links
Rigel Announces Pricing of Public Offering of Common Stock
Date:5/26/2011

).

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Rigel Pharmaceuticals, Inc.
Rigel, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as for muscle disorders.

Forward-Looking Information is Subject to Risk and Uncertainty

Certain of the statements made in this press release are forward looking, such as those, among others, relating to Rigel's expectations regarding the completion, timing and size of the public offering and the amount of gross proceeds to be received. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, risks and uncertainties related to market and other conditions, the satisfaction of customary closing conditions related to the public offering and the impact of general economic, industry or political conditions in the United States or internationally. There can be no assurance that Rigel will be able to complete the public offering at the anticipated size or on the anticipated terms, or at all. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release.  Additional risks and uncertainties relating to the offering, Rigel and its business can be found under the heading "Risk Factors" in Rigel's Quarterly Report on Form 10-Q filed with the SEC on May 3, 2011 and other filings with the SEC, in the preliminary prospectus supplement related to the o
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Rigel Announces Proposed Public Offering of Common Stock
2. Rigel to Present at Bank of America Merrill Lynch Health Care Conference
3. Rigel Announces First Quarter Financial Results
4. Rigel Announces Fourth Quarter and Year End 2010 Financial Results
5. Rigel to Present at Three Upcoming Investor Conferences
6. Rigel Announces Participation at Two Investor Conferences
7. Rigel to Present at JP Morgan Healthcare Conference
8. Rigel Announces Third Quarter 2009 Financial Results
9. Rigel Announces Presentations at Two Investor Conferences
10. Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
11. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 The National ... the latest results achieved by the real-time, pseudoephedrine ... the National Precursor Log Exchange (NPLEx), automatically blocks ... track down meth offenders and make arrests. Data ... Kansas blocked the sale of ...
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com announces ... in its catalogue: The Impact of ... http://www.reportlinker.com/p01618927/The-Impact-of-Healthcare-Reform-PPACA-On-the-US-IVD-Industry.html ... 3590) is complex legislation that affects virtually every ... provisions are beginning to take effect now. IVD ...
(Date:8/20/2014)... 20, 2014 Research and Markets ... "Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and ... report to their offering. A ... and geography) - Size, Share, Global Trends, Company ... and Forecast, 2013 - 2020", suggests that the ...
Breaking Medicine Technology:Kansas's Stop-Sale System Achieves Significant Results In Battle Against Meth 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 3The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 4The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 5The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 6Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography) - Research Report, 2013 - 2020 2
... 2012  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today ... 2012.  For the first quarter of 2012, the Company reported ... compared with a net income of $2.9 million, or $0.05 ... $3.8 million change in operating results is primarily due to ...
... Janssen Research & Development, LLC, (Janssen), announced today ... to the U.S. Food and Drug Administration (FDA) seeking ... an oral anticoagulant, to treat patients with deep vein ... recurrent venous thromboembolism (VTE). These submissions are ...
Cached Medicine Technology:Neurocrine Biosciences Reports First Quarter 2012 Results 2Neurocrine Biosciences Reports First Quarter 2012 Results 3Neurocrine Biosciences Reports First Quarter 2012 Results 4Neurocrine Biosciences Reports First Quarter 2012 Results 5Neurocrine Biosciences Reports First Quarter 2012 Results 6Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 2Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 3Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 4Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 5Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 6Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 7Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 8
(Date:8/20/2014)... Denver, Colorado (PRWEB) August 21, 2014 ... filled with celebrities making pleas for donations to fight ... funds will be well-known national companies and brands through ... the public’s, the 2013 MDA Telethon raised nearly $60 ... as Zinga Frozen Yogurt franchisees, cause-related marketing ...
(Date:8/20/2014)... 21, 2014 Recently, UWDress.com, the distinguished ... selection of birthday party dresses for girls . ... are well-designed and exquisitely handmade by experienced specialists. Now, ... percent off. , The company’s new items come in ... short knee length frocks, long elegant backless gowns and ...
(Date:8/20/2014)... 2014 The International Board ... an organization recognizing professionals dedicated to promoting quality ... that with a certificate in autism , ... the Autism Spectrum have a way to show ... This, in turn, say IBCCES representatives, increases the ...
(Date:8/20/2014)... 19, 2014 (HealthDay News) -- A group representing U.S. ... a flu shot. According to the American College ... recent years have upheld the safety and effectiveness of ... highly infectious and can be particularly dangerous to pregnant ... other complications," Dr. Laura Riley, chair of the college,s ...
(Date:8/20/2014)... that the immune system is defective in people suffering from ... have ongoing issues with pain. , The research the ... help to explain why some painkillers may not offer satisfactory ... to 10% of the community. There are different forms ... which often has the greatest impact on sufferers, quality of ...
Breaking Medicine News(10 mins):Health News:On Eve of Big Telethon, Froyo Businesses Participate but Also Go Their Own -- Local Way 2Health News:On Eve of Big Telethon, Froyo Businesses Participate but Also Go Their Own -- Local Way 3Health News:Cheap Birthday Party Dresses for Girls Now Available at UWDress.com 2Health News:National Autism Certificate Credentialing Board IBCCES Increases Job Placement Opportunities for Those Dedicated to Working Within the Autism Spectrum 2Health News:National Autism Certificate Credentialing Board IBCCES Increases Job Placement Opportunities for Those Dedicated to Working Within the Autism Spectrum 3Health News:All Pregnant Women Need Flu Shot: Ob/Gyn Group 2Health News:Pain treatments less effective for those with irritable bowel 2
... on knees can also repair damaged ankles claim the ... repairing knee injuries, but it is also a valuable ... minimally invasive surgical technique it is being applied in ... problems, including ligament damage, bone chips and recurrent pain ...
... disease, is becoming an elite disease as so much of ... As a result of such ongoing research, hyperhomocysteinemia (increased levels ... the risk factors.// ,Dr. O Mayer Jr and colleagues ... result of their study that beer may provide enough folate--a ...
... pharmaceutical companies hope to strike a pot of gold ... price war that is likely to escalate in coming ... lured many companies to develop anti-AIDS drugs and market ... to pricing. ,The anti-AIDS drug market, currently dominated ...
... is injurious to health"- this warning , printed in every cigarette ... of smoking in many. But now the fact that even a ... by the researchers of North Carolina. ,It is a well ... the diseases such as heart attack , cancer etc.,. ...
... little as 10 minutes of moderate exercise daily can improve mood ... fact that exercise has its benefit towars the physical asset. But ... as to how much exercise will benefit. This is based on ... bicycle for longer periods and did not find any benefits as ...
... and ulcerative colitis, often grouped together under inflammatory ... industrialized nations with stringent standards of public hygiene. ... human immune system from interacting with worms, bacteria ... properly...Yes! Doctors at the University of Iowa are ...
Cached Medicine News:Health News:Arthroscopy for Ankles 2Health News:WORM! WORM! all the way 2
... This type of anchor is generally utilized when ... directly into the bone. Unlike other anchors that ... anchor does not have that limitation. The only ... is a mallet. The 4.4mm Stainless Steel Anchor ...
... Yasushi Nakao, M.D., Smith & Nephew ... flexor,tendon release for fingers and thumbs ... approach is designed to decrease patient ... of releasing the A1 pulley under ...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Medicine Products: